NURIX THERAPEUTICS, INC. Increase (Decrease) in Contract with Customer, Asset
NURIX THERAPEUTICS, INC. (NRIX) reported Increase (Decrease) in Contract with Customer, Asset of $2.00 million for the 3-month period ending 2022-02-28, per its 10-Q filed 2022-04-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerAsset · last filed 2022-04-08
- NURIX THERAPEUTICS, INC. increase (decrease) in contract with customer, asset for the quarter ending 2022-02-28 was $2.00M.
- NURIX THERAPEUTICS, INC. increase (decrease) in contract with customer, asset for the quarter ending 2021-11-30 was -$5.00M.
- NURIX THERAPEUTICS, INC. increase (decrease) in contract with customer, asset for the quarter ending 2021-08-31 was $5.00M.
- NURIX THERAPEUTICS, INC. increase (decrease) in contract with customer, asset for the quarter ending 2021-05-31 was $0.00.
- NURIX THERAPEUTICS, INC. increase (decrease) in contract with customer, asset for fiscal 2021 was -$7.50M, a 200.00% decline from fiscal 2020.
- NURIX THERAPEUTICS, INC. increase (decrease) in contract with customer, asset for fiscal 2020 was $7.50M.
| Period end | Increase (Decrease) in Contract with Customer, Asset 3 month | Increase (Decrease) in Contract with Customer, Asset 6 month | Increase (Decrease) in Contract with Customer, Asset 9 month | Increase (Decrease) in Contract with Customer, Asset 12 month |
|---|---|---|---|---|
| 2022-02-28 | $2.00M 10-Q · filed 2022-04-08 | -$3.00M derived: sum of 2 quarters · filed 2022-04-08 | $2.00M derived: sum of 3 quarters · filed 2022-04-08 | $2.00M derived: sum of 4 quarters · filed 2022-04-08 |
| 2021-11-30 | -$5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $0.00 derived: sum of 2 quarters · filed 2022-01-28 | $0.00 derived: sum of 3 quarters · filed 2022-01-28 | -$7.50M 10-K · filed 2022-01-28 |
| 2021-08-31 | $5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-14 | $5.00M derived: sum of 2 quarters · filed 2021-10-14 | -$2.50M 10-Q · filed 2021-10-14 | |
| 2021-05-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-13 | -$7.50M 10-Q · filed 2021-07-13 | ||
| 2021-02-28 | -$7.50M 10-Q · filed 2022-04-08 | |||
| 2020-11-30 | $7.50M 10-K · filed 2022-01-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |